Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Cash from Financing Activities (2021 - 2025)

InMed Pharmaceuticals' Cash from Financing Activities history spans 5 years, with the latest figure at -$137178.0 for Q3 2025.

  • For Q3 2025, Cash from Financing Activities fell 116.37% year-over-year to -$137178.0; the TTM value through Dec 2025 reached $11.0 million, up 831.0%, while the annual FY2025 figure was $12.3 million, 163.66% up from the prior year.
  • Cash from Financing Activities reached -$137178.0 in Q3 2025 per INM's latest filing, down from $8.2 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $10.9 million in Q3 2021 to a low of -$836144.0 in Q4 2021.
  • Average Cash from Financing Activities over 5 years is $2.9 million, with a median of $838239.0 recorded in 2024.
  • Peak YoY movement for Cash from Financing Activities: plummeted 117.31% in 2023, then surged 4644531.25% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at -$836144.0 in 2021, then surged by 735.69% to $5.3 million in 2022, then plummeted by 101.2% to -$63697.0 in 2023, then surged by 631.46% to $338521.0 in 2024, then tumbled by 140.52% to -$137178.0 in 2025.
  • Per Business Quant, the three most recent readings for INM's Cash from Financing Activities are -$137178.0 (Q3 2025), $8.2 million (Q2 2025), and $2.9 million (Q1 2025).